RxDoctor Payments Data

Marcia Diaz

Family · Vinita, OKNPI 1558347328

Payments from drug & device makers

$459in general payments, 2019–2025

Across 28 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$241
  • Boehringer Ingelheim$60
  • Novo Nordisk$39
  • Dexcom, Inc.$38
  • Novartis$21
  • Johnson & Johnson$16
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$459 in reported general payments places this provider in the 55th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$49,399
Medicare patients
236
Services billed
1,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$52,090
JanuviaSitagliptin Phosphate34$29,434
OzempicSemaglutide23$21,739
JardianceEmpagliflozin12$21,381
MounjaroTirzepatide14$19,739
LinzessLinaclotide12$17,008
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,524
FarxigaDapagliflozin Propanediol11$10,514
XareltoRivaroxaban11$8,406
Penciclovir13$8,328
Tolterodine Tartrate ErTolterodine Tartrate55$4,775
Rosuvastatin Calcium154$4,597
SymbicortBudesonide/Formoterol Fumarate19$4,499
Insulin Lispro Kwikpen U-100Insulin Lispro14$3,279
Gabapentin173$3,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$52,09064 claims
Novo NordiskOzempic$39$21,73923 claims
Boehringer IngelheimJardiance$60$21,38112 claims
AbbVieLinzess$241$17,00812 claims
GSKTrelegy Ellipta$16$15,52424 claims
Johnson & JohnsonXarelto$16$8,40611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,026 family providers in Oklahoma.

Other family in Vinita

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →